Patents Assigned to JCR Pharmaceuticals Co., Ltd.
  • Patent number: 5547945
    Abstract: A remitting agent for nephrotic syndrome and hepatopathy symptoms is provided that which comprises water-soluble polysaccharides having poly-D-galacturonic acid as an effective constituent; polysaccharides having the following characteristic properties which are extractable from Tanjin with water or an aqueous solvent:A. Sugar content: 60 to 100%.(1) Sugar composition:40 to 80% of uronic acid (composed almost entirely of D-galacturonic acid) and10 to 30% of neutral sugars(2) Neutral sugar composition:0 to 15% of rhamnose0 to 15% of glucose25 to 55% of galactose30 to 60% of arabinose0 to 15% of mannoseB. Molecular weight: 150,000 to 300,000; the invention also provides a process for producing the above-described polysaccharides which comprises allowing an aqueous extract of Tanjin to pass through a porous polymeric resin, followed by purification through gel filtration chromatography.
    Type: Grant
    Filed: July 7, 1994
    Date of Patent: August 20, 1996
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Guoji Ye, Jun-ichi Kajihara, Sei Kirihara, Kazuo Kato, Hiroko Abe
  • Patent number: 5514647
    Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: May 7, 1996
    Assignees: New York Blood Center, Inc., JCR Pharmaceuticals Co., Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Bernard Horowitz, Richard W. Shulman, Adrianne J. Setton, Toyohiko Nishimura, Yoichi Kawashima
  • Patent number: 5504065
    Abstract: Human urine trypsin inhibitor is provided as an agent for treating acquired immunodeficiency syndrome (AIDS), preventing the infection with AIDS or preventing the onset of AIDS after such infection. It can be administered intravenously for the treatment and externally for the prevention.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: April 2, 1996
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Toshio Hattori, Kiyoshi Takatsuki, Yoshikazu Yuki
  • Patent number: 5403731
    Abstract: A modified superoxide dismutase represented by the formula: ##STR1## (wherein R is as defined below; SOD is a residue of superoxide dismutase) is produced, in a shortened period of reaction with a high and constant modification ratio, by reacting a polymeric carbonyldiimidazole derivative represented by the formula: ##STR2## (wherein R is a residue of a water soluble polymer having an average molecular weight of about 2,000 to 10,000) with superoxide dismutase in the presence of a buffer having a pH of 9.0 to 11.0 and a concentration of 0.1 M to 0.5 M, preferably 0.2 M to 0.4 M, at a temperature of 30.degree. to 70.degree. C., preferably 45.degree. to 60.degree. C. The modified superoxide dismutase thus produced exhibits a suitably prolonged blood half-life.
    Type: Grant
    Filed: December 3, 1993
    Date of Patent: April 4, 1995
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Yoshiyuki Nakano, Hajime Hiratani, Kazuo Kato
  • Patent number: 5371196
    Abstract: Secretory immunoglobulin A preparations substantially not containing virus are produced by a process wherein secretory immunoglobulin A which might be contaminated with viruses is (1) heated about 60.degree. C. for about 10 hours, or (2) subjected to the reaction with tri-n-butyl phosphate and a surfactant and the heating as mentioned above, as liquidized form in an aqueous medium, and then polymerized matters are precipitated from the resulting solution by adding polyethyleneglycol thereto.
    Type: Grant
    Filed: September 1, 1993
    Date of Patent: December 6, 1994
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Yoshikazu Yuki, Motoko Baba, Mitsuo Shimizu, Kazuo Kato, Hajime Hiratani
  • Patent number: 5348939
    Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method of treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.
    Type: Grant
    Filed: May 11, 1993
    Date of Patent: September 20, 1994
    Assignees: New York Blood Center, Inc., JCR Pharmaceuticals Co., Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Bernard Horowitz, Richard W. Shulman, Adrianne J. Setton, Toyohiko Nishimura, Yoichi Kawashima
  • Patent number: 5296223
    Abstract: There are provided thrombolytic agents suited for oral administration. The agent comprises a proteolytic enzyme of subtilisin family, such as subtilisin BPN', subtilisin Carsberg, subtilisin amylosacchariticus, etc., produced by microorganisms belonging to genus Bacillus, such as Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, etc. and, even when administered orally, exhibits thrombolytic activity.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: March 22, 1994
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Koichiro Nakanishi, Hajime Hiratani, Kazuo Kato
  • Patent number: 5283239
    Abstract: LEM which is an aqueous extract of a mycelial culture of Lentinus Edodes and has a sugar composition composed of arabinose, xylose, glucose, mannose, galasctose, fucose and rhamnose, as well as a fraction of LEM which corresponds to molecular weights of 10,000 to 1,000,000 daltons and has a sugar composition composed of arabinose, xylose, glucose, mannose and galactose are provided as agents for inhibiting the adsorption of herpesviruses such as herpes simplex to the cells.
    Type: Grant
    Filed: January 14, 1992
    Date of Patent: February 1, 1994
    Assignees: JCR Pharmaceuticals Co. Ltd., Noda Shokukin Kogyo Co., Ltd.
    Inventors: Junichi Koga, Yasuhiro Ohashi, Hajime Hiratani
  • Patent number: 5281577
    Abstract: An inhibitor of the proliferation of herpesviruses and of the recurrence of affections caused by their latent infection, which is an active material obtained by fractional purification of the aqueous extract from cultured Lentinus edodes mycelia.
    Type: Grant
    Filed: October 15, 1992
    Date of Patent: January 25, 1994
    Assignees: JCR Pharmaceuticals Co., Ltd., Noda Shokukin Kogyo Co., Ltd.
    Inventors: Junichi Koga, Yasuhiro Ohashi, Hajime Hiratani
  • Patent number: 5240864
    Abstract: Antiserum which can recognize all subtypes of human leukocyte interferon is prepared from the blood of an animal immunized with partially purified human leukocyte interferon obtained from a culture of human leukocyte stimulated with Sendai virus.The antiserum is added to a column whereon concentrated culture broth of human leukocyte has been immobilized to adsorb impurities, the effluent is added to a column whereon partially purified human leukocyte interferon has been immobilized to adsorb anti-human leukocyte interferon antibody and then the antibody is eluted from the column.The antibody thus obtained recognizes all subtypes of human leukocyte interferon and can be separated by a chromatography to each monoclonal antibody which recognizes a single subtype.Employing these antibodies, the subtypes of human leukocyte interferon or their antibodies in a sample can be analized or assayed.
    Type: Grant
    Filed: December 4, 1990
    Date of Patent: August 31, 1993
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Junichi Koga, Hiroyuki Shirono, Akio Matsuo, Hajime Hiratani